This is a contract result notice, not an open opportunity. Details from the official award data.

NHSEISW (The Commissioner) sought to re-commission two Diabetic Eye Screening Programmes (DESP) to deliver screening to the eligible populations of Bath & North East Somerset, Swindon and Wiltshire (Lot 1) and the eligible population of Dorset (Lot 2).

The eligible population of both Lots includes patients over the age of 12 diagnosed with diabetes and registered with, or eligible to be registered with a GP, as well as individuals within prisons, secure units and the armed forces.

The aim of the DESP is to reduce the risk of sight loss amongst people with diabetes by the prompt identification and effective treatment if necessary, of sight threatening diabetic retinopathy.

This will be achieved by delivering an evidence-based service that: •Identifies the eligible population and ensures effective delivery with maximum coverage •Is safe, effective, high quality, externally and independently monitored, and quality assured •Leads to earlier detection, appropriate referral, effective treatment and improved outcomes •Is delivered and supported by suitably trained, competent and qualified clinical and non-clinical staff who, where relevant, participate in recognised ongoing continuing medical education (CME), continuous professional development (CPD) and quality assurance (QA) schemes •Has audit embedded in the service •Works effectively with other stakeholders to ensure the care pathway is smooth and efficient.

There are 3 key elements of service delivery, namely: •Call/recall for all people with diabetes invited for routine digital screening - this is currently undertaken on an annual basis but screening intervals are likely to extend to two years for people at low risk during the contract term in line with national guidance •Digital surveillance where individuals need more frequent screening •Slit lamp bio-microscopy (SLB) for those individuals where normal photography is inappropriate (e.g. those having cataracts).

Optical Coherence Tomography (OCT) does not form part of this Contract at this time, though this position may change over the life of the contract in line with national guidance.

The Contract term will be 5 years, with an option to extend for a further 3 years at the sole discretion of the Commissioner.

The Contracts will commence on 01/04/2022.

The 8 year estimated expected contract values based on predicted activity levels are; Lot 1 = £11,311,233.60 Lot 2 = £10,985,831.92 The Contract will operate on a hybrid basis with a fixed "block" element based upon the average uptake of routine screening in the eligible population for the last 2 years plus a variable element for digital surveillance and SLB and a further variable element to incentivise routine screening uptake to 85%.

Variable elements will be paid according to activity undertaken.

The Commissioner's ambition through the financial model is to encourage uptake of DESP to achieve or exceed the national achievable target of 85% uptake in routine screening (DE1).